News
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.
FEATURED STORIES
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.
Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
The company’s co-Founder, President and CEO Dr. P. Peter Ghoroghchian, took time to discuss the company and the financing round with BioSpace.
Funds are always flowing in the life science industry. Here’s where the money’s headed this week.
Werewolf Therapeutics is designing and developing molecules that unleash the natural ferocity of cytokines for the treatment of cancer.
Enveda Biosciences believes the answers to humanity’s most challenging diseases can be found by harnessing the complexity of the natural world.
Gilead Sciences reported that about $250 million of counterfeit versions of its HIV drugs, Biktarvy and Descovy, were sold to pharmacies over two years.
The SPAC announced it is merging with medical technology company ProKidney LP, in a deal that values the combined equity of the companies at $2.64 billion.
Moderna is poised to commercialize its COVID-19 and influenza combination vaccine by the fall of 2023, with some potential for the same drug to also be viable against the RSV.
The agency recommended another clinical trial be conducted to confirm the data from the study on the 3.2-mg dose of the intranasal carbetocin for Prader-Willi syndrome.
Amagma Therapeutics announced a licensing agreement with Innovent Biologics for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC Platform.
Based on the success of a joint immuno-oncology antibody collaboration program targeting CD96, GlaxoSmithKline and 23andMe have extended their 2018 collaboration for an additional year.